Efficacy of percutaneous transluminal coronary recanalization utilizing streptokinase thrombolysis in patients with acute myocardial infarction.

Since coronary thrombosis is a principal factor in the evolving necrotic process in the majority of patients with acute myocardial infarction (AMI), a prospective study was conducted in 25 AMI patients who underwent expeditious coronary arteriography. Of these patients, 22 with totally occluding thrombus also received early streptokinase (STK) administration. STK was given by intracoronary (20 patients) or systemic (two patients) infusion, 2000 to 50,000 IU/min, to a total dose of 125,000 to 500,000 IU within 10 hours of AMI symptom onset. Eighteen patients had angiographically visualized successful coronary thrombolysis; the shorter the interval between onset of symptoms to treatment, the more rapid was the clot dissolution. Successful thrombolysis occurred concomitantly with readily managed reperfusion ventricular tachyarrhythmias in nearly all patients. In addition, STK recanalization resulted in relief of ongoing chest pain in 10 of 12 patients, 10 of 16 evidenced immediate normalization of hyperacute ST segment abnormalities, and 8 of 14 demonstrated subsequent improvement of angiographically visualized left ventricular (LV) ejection fraction. In the percutaneous transluminal coronary recanalization (PTCR) procedure, the step of using a soft-tipped guide wire itself was transiently useful in only one of seven patients in whom this was attempted; reocclusion took place without added STK therapy. Nitroglycerin (NTG) alone produced only slight distal patency in but 1 of 19 patients with coronary occlusion given the nitrate. Importantly, in 14 control AMI patients receiving conventional treatment without STK, 10 showed angiographically complete occlusion of the coronary artery supplying the infarct region 1 month after infarction, thereby excluding spontaneous clot lysis mimicking STK-PTCR-induced reperfusion. These data support the concept that coronary occlusion by thrombosis is inherently involved with AMI and that rapid PTCR application of intracoronary STK provides potent thrombolysis, superior to that provided by NTG and guide wire passage in reestablishing coronary flow with attendant salvage of jeopardized myocardium and with subsequently improved LV function.

Evaluation of platelet kinetics following porcine and mechanical valve replacement.

Because thromboembolic pathogenesis in mechanical prosthetic valves (MP) might involve selective MP platelet consumption with consequent reduced platelet survival, it has been suggested that lowered platelet half-life (T 1/2) detection provides identification of postoperative thrombotic risk. Porcine heterografts (PH) possess less thromboembolic hazards than MP; thus, comparative evaluation of PH versus MP platelet T 1/2 is germane to the test's thrombotic predictive value, yet platelet kinetics in PH require elucidation. Accordingly, 51chromium platelet T 1/2 was determined in 16 patients with substituted valves (10 PH and 6 MP). Average platelet T 1/2 in PH (2.9 +/- 0.6 d) was similar (p greater than 0.05) to MP (3.2 +/- 0.6 d), and both were considerably lower (p less than 0.05) than platelet T 1/2 in normal subjects (NL, 5.1 +/- 0.5 d). Furthermore, platelet T 1/2 was below the lowest NL platelet T 1/2 (4.0 d) in seven PH and three MP patients. Thus, frequency and extent of decreased platelet survival in PH are common and equal to MP. These results indicate that platelet half-life does not afford thromboembolic predictability in patients with mechanical valves and, instead, favors prosthetic-induced physical trauma causing abnormal platelet survival.

Intra-aortic balloon counterpulsation: rationale, application and results.

Intra-aortic balloon counterpulsation is an effective means of reducing myocardial ischemia and supporting the failing circulation. Its therapeutic benefits are the direct result of distolic augmentation and systolic unloading, the former increasing myocardial perfusion and the latter enhancing cardiac performance. Indirect effect include diminution of ischemia by decrease in the determinants of myocardial oxygen demand and improved ventricular function secondary to the decreased ischemia. Intra-aortic balloon counterpulsation is indicated in clinical syndromes related to intractable cardiac ischemia, including myocardial infarction shock and severe left ventricular failure, refractory ischemic pains, and ventricular arrhythmias unresponsive to medical management. It is also of importance in other situations associated with low cardiac output. This therapeutic modality has recently been considered for early use in extensive myocardial infarction to limit cardiac damage and avert complications. Recent technical advances have facilitated the ease and safety of application of intra-aorta balloon counterpulsation. Complication are of low frequency but can be serious and employment of the method is predicated upon consideration of both potential benefits and risks.

Cross-sectional echocardiography: physical principles, anatomic planes, limitations and pitfalls.

Although M mode echocardiography has achieved a prominent role in the diagnosis and management of patients with cardiovascular disease, the limited area of view afforded by M mode techniques has restricted the application of ultrasound in many areas. The development of two dimensional echocardiography has obviated many of the limitations inherent in the narrow view of the M mode technique. It has enabled imaging of the heart from additional transducer locations, permitted determination of shape and anatomy and provided the ability to determine motion along two axes. Several types of two dimensional echocardiographs have been developed, and each type offers both advantages and disadvantages. Although two dimensional echocardiography has provided a larger area of view with ultrasound, it has also introduced new limitations including a larger and bulkier transducer, a much reduced sampling rate and a difficult display medium (videotape). In addition, new considerations regarding ultrasonic resolution have been raised. Two dimensional techniques have resulted in new pitfalls in ultrasonic diagnosis related to instrument artifacts as well as to performance and interpretation of the examination. The spurious appearance of cardiac masses because of these ultrasonic artifacts represents a particularly prominent diagnostic pitfall that must be avoided in daily practice. It is anticipated that the new wider field of view provided by two dimensional echocardiography combined with a standard high resolution capability of ultrasound (2 to 4 mm) will result in an increasingly large role for echocardiography in the management of patients with heart disease.

Plasma high density lipoproteins and coronary artery disease.

Plasma lipid samples and other atherosclerosis risk factors were related to presence of extent of coronary artery disease (CAD) in 102 consecutive patients undergoing coronary angiography. Thirty-six were without CAD and 66 had angiographically documented CAD. In CAD, high density lipoprotein (HDL) cholesterol was lower and total cholesterol and low density lipoprotein cholesterol were higher than in subjects without CAD. Further, HDL was inversely related to extent of CAD (number of major obstructed vessels). Moreover, decreased HDL was the single most important determinant of CAD among all atherosclerosis risk factors (more so in females than in males). In addition, reduced plasma enzymatic activity of lecithin:cholesterol acyltransferase (LCAT) correlated with the presence and extent of angiographically shown CAD. These findings document the protective effect of elevated plasma HDL against coronary obstructive disease and suggest this salutary action may be related to LCAT mobilization of cholesterol from atherosclerotic lesions.

Evaluation of transluminal angioplasty of chronic coronary artery stenosis. Value and limitations assessed in fresh human cadaver hearts.

The possibility of increasing reduced blood flow in atherosclerotic coronary obstruction by catheter balloon dilatation offers a nonsurgical approach to relieve clinical coronary stenosis. To assess the ability of effectively dilating such diseased vessels by transluminal angioplasty, we used the Grüntzig balloon-tipped catheter in 12 fresh human cadaver hearts in which the intervention was performed in 21 noncalcified stenotic areas, including each of the three major coronary arteries. Quantitative coronary arteriography documented decreased obstruction of each lesion; luminal diameter increased 58% (1.9 +/- 0.2 mm to 2.8 +/- 0.3; p less than 0.001) and luminal diameter relative to the most proximal normal coronary segment diminished 61% (46 +/- 4% to 18 +/- 3%; p less than 0.001). Angioplasty was most successfully applied in proximal, discrete, noncalcified lesions of the right and left anterior descending coronaries; calcified, tortuous, middle and distal lesions and the left circumflex coronary were entered with difficulty or unapproachable. Histologic examination revealed microanatomic changes, most often endothelial disruption and atheroma compression, but no serious vascular tears. Dilatation beyond normal coronary diameter caused vessel rupture. This study extends elucidation of the value and limitations of percutaneous transluminal angioplasty in the clinical use of this technique in selected patients for relieving coronary obstruction without surgery.

Hemodynamic assessment of the new aortic Carpentier-Edwards bioprosthesis.

Although glutaraldehyde-preserved porcine aortic Hancock heterografts have lower thromboembolism incidence than mechanical aortic valves, Hancock xenografts provide less functional aortic outflow orifices and thereby greater transvalvular gradients than mechanical prostheses. The newly developed aortic Carpentier-Edwards porcine heterografts comprise a thin-walled Elgiloy flexible metal stent covered with Teflon which provides somewhat wider internal orifices than aortic Hancock valves of the same external annulus diameter. Since aortic Carpentier-Edwards xenografts have not been clinically evaluated previously, the present study assessed cardiac function and heterograft performance (1.7 months postoperation) and clinical status (4.2 months postoperation) of 19 patients with severe aortic stenosis and/or regurgitation prior to surgery. Left ventricular end-diastolic pressures decreased (17 to 9 mm Hg), cardiac index remained normal, and clinical symptomatology diminished markedly. Mean peak transxenograft systolic pressure was only 16 mm Hg (valve area 1.73 cm2), without meaningful regurgitation. Thus aortic Carpentier-Edwards bioprostheses provide generally excellent heterograft function which appears more favorable than previous reports of Hancock xenografts.

Combined dopamine and nitroprusside therapy in congestive heart failure. Greater augmentation of cardiac performance by addition of inotropic stimulation to afterload reduction.

The hemodynamic benefits of combining administration of dopamine with nitroprusside (NP) were evaluated in nine patients with chronic congestive heart failure due to ischemic, idiopathic myocardial or valvular cardiac disease. NP alone (68 microng/min) produced decline in left ventricular end-diastolic pressure (LVEDP) from 25.4 to 14.1 mm Hg (p less than 0.01) but modest increase in cardiac index (CI) from 2.41 to 3.02 L/min/m2 (P less than 0.05). Dopamine alone (6 microng/kg/min) caused an elevation of CI to 3.36 (P less than 0.01) but without decrease of LVEDP. Simultaneous infusion of the two agents resulted in favorable alterations in both hemodynamic variables: LVEDP decreased to 15.7 (P less than 0.01) and CI increased to 3.52 (P less than 0.01). It is concluded that dopamine substantially enhances the effectiveness of nitroprusside therapy in congestive heart failure by providing concomitantly the principal beneficial actions of the vasodilator and dopamine used separately. Thus combined dopamine with NP treatment considerably raises low CI while markedly reducing elevated LVEDP and provides a potentially efficacious pharmacologic modality for the treatment of severe congestive heart failure due to left ventricular dysfunction.